`Atty. Docket No.: GWLG-017US-CIP
`Response to Non-Final Office Action
`
`AMENDMENT TO THE CLAIMS
`
`This listing of claims will replace all prior versions, and listings, of claims in the
`
`application. The following amendments do not constitute an admission regarding the
`
`patentability of the amended subject matter and should not be so construed.
`
`Please amend the claims as follows:
`
`l-12.
`
`(Canceled)
`
`l3.
`
`(Currently Amended) A method comprising:
`
`contacting a sample from a mammal with a glycodelin antibody and an antibody to
`
`one or more of brain-derived neurotrophic factor (BDNF), zinc-alpha-Z-glycoprotein
`
`(ZAG), and cancer antigen 125 (CA-125),
`
`detecting binding between the glycodelin antibody and glycodelin and between the
`
`antibody to one or more of BDNF, ZAG and CA-125 and one or more of BDNF, ZAG and
`
`
`CA-125, respectively; and
`
`determining levels of glycodelin and one or more of BDNF, ZAG CA-125 in the
`
`sample based on the antibody binding—and
`
`
`
`(Previously Presented) The method of claim 13, wherein levels of ZAG and CA125 are
`
`determined in the sample.
`
`(Previously Presented) The method of claim 13, wherein the level of circulating BDNF is
`
`determined in the sample.
`
`14.
`
`15.
`
`
`
`US. Serial No.: 15/632,497
`Atty. Docket No.: GWLG-017US-CIP
`Response to Non-Final Office Action
`
`16.
`
`17.
`
`(Previously Presented) The method of claim 15, wherein the level of ZAG is determined
`
`in the sample.
`
`(Currently Amended) A method of determining levels of circulating BDNF and CA-125 in
`
`a mammal comprising:
`
`
`detecting the presence of brain-derived neurotrophic factor (BDNF) and cancer
`
`
`antigen 125 (CA-125) in a blood serum or plasma sample from the mammal by contacting
`
`the sample with an anti-BDNF antibody and an anti-CA-125 antibody;
`
`detecting binding between the anti-BDNF antibody and BDNF and between the
`
`anti-CA-125 antibody and CA-125 in the sample; and
`
`determining the circulating levels of BDNF and CA-125 in the Wmammal
`
`based on the amount of antibody binding.
`
`18-25
`
`(Canceled).
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`(New) The method of claim 17, wherein the sample is a plasma sample.
`
`(New) The method of claim 17, wherein the mammal is a human.
`
`(New) The method of claim 17, wherein the BDNF is mature BDNF (mBDNF).
`
`(New) The method of claim 28, wherein the mBDNF has the amino acid sequence of SEQ
`
`ID NO: 1 and/or is encoded by the transcript sequence of SEQ ID NO: 5.
`
`(New) The method of claim 17, wherein the method comprises an enzyme-linked
`
`immunosorbent assay (ELISA).
`
`(New) The method of claim 17, additionally comprising the detection of one or both of
`
`glycodelin and zinc-alpha-2-glycoprotein (ZAG).
`
`(New) The method of claim 31, wherein the mammal is human.
`
`
`
`US. Serial No.: 15/632,497
`Atty. Docket No.: GWLG-017US-CIP
`Response to Non-Final Office Action
`
`33.
`
`(New) The method of claim 32, wherein the mBDNF has the amino acid sequence of SEQ
`
`ID NO: 1 and/or is encoded by the transcript sequence of SEQ ID NO:5, the glycodelin has
`
`the amino acid sequence of SEQ ID NO: l3, 14 or 15 and/or is encoded by the transcript
`
`sequence of SEQ ID NO: l6, 17 or 18; and the ZAG has the amino acid sequence of SEQ
`
`ID NO: 19 and/or is encoded by the transcript sequence of SEQ ID NO: 20.
`
`(New) The method of claim 17, wherein the anti-BDNF antibody and anti-CA-125
`
`antibody is selected from a polyclonal antibody, a monoclonal antibody and an antigen-
`
`binding fragment.
`
`(New) The method of claim 13, wherein circulating levels of ZAG and BDNF are
`
`determined in the sample.
`
`(New) The method of claim 13, wherein the method comprises an enzyme-linked
`
`immunosorbent assay to detect circulating levels of glycodelin and one or more of BDNF,
`
`ZAG and CA125.
`
`(New) The method of claim 13, wherein the glycodelin antibody and the antibody to one
`
`or more of BDNF, ZAG and CA-125 is selected from a polyclonal antibody, a monoclonal
`
`antibody and an antigen-binding fragment.
`
`(New) The method of claim 13, wherein the sample is a blood, serum or plasma sample.
`
`(New) The method of claim 13, wherein the mammal is a human.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`39.
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
